Chlora Aceso Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
About Chlora Aceso Pharmaceuticals
Chlora Aceso Pharmaceuticals Private Limited (CAPPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 May 2016 (Eight years and nine months 1 days old ). Its registered office is in Kaushambi, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
James Kaushar and Shabana Yasmeen serve as directors at the Company.
Company Details
-
Location
Kaushambi, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999UP2016PTC082857
-
Company No.
082857
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
02 May 2016
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
What products or services does Chlora Aceso Pharmaceuticals Private Limited offer?
Chlora Aceso Pharmaceuticals Private Limited offers a wide range of products and services, including Anti Inflammatory Drugs, Trypsin Chymotrypsin Tablet, Anti Infective Drugs & Medicines, Antibacterial Drugs, Anti Ulcer Drugs, Rabeprazole Injection, Digestive System Drugs & Medicines, Laxatives, Brain & Nervous System Drugs, Antiepileptic Drugs.
Who are the key members and board of directors at Chlora Aceso Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shabana Yasmeen
|
Director | 02-May-2016 | Current |
|
James Kaushar
|
Director | 02-May-2016 | Current |
Financial Performance of Chlora Aceso Pharmaceuticals.
Chlora Aceso Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Chlora Aceso Pharmaceuticals?
In 2017, Chlora Aceso Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Chlora Aceso Pharmaceuticals?
Unlock and access historical data on people associated with Chlora Aceso Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Chlora Aceso Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Chlora Aceso Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
